The Logic Behind a Urine-Based Dementia Screen

One Step Dementia Risk Test Kit

Dementia diagnosis has long been an expensive, late-stage affair — reliant on PET scans, lumbar punctures, or cognitive batteries that demand specialist time. The emerging alternative is biomarker screening, and China is now producing a commercial test that makes this logistically simpler.

The One Step Dementia Risk Test Kit uses colloidal gold lateral immunochromatography to detect Aβ concentration in urine. It is a non-invasive IVD, certified CE, NMPA, and MDA, that returns a result in ten minutes from a fresh midstream urine sample. No lab infrastructure is required beyond a basic clinic.

The kit reports 79.14 percent sensitivity and 91.03 percent specificity against clinical reference, with a Kappa value of 0.704 — a meaningful performance for a screening triage tool. It is intended for adults aged 45 and above, including those with chronic conditions or family history that elevate risk.

The product’s core technology lies in its proprietary Aβ monoclonal antibody and an antibody-polymer sandwich method that concentrates biomarker capture in a high-background matrix like urine. This is where the manufacturing value sits — not in the test strip, but in the reagents.

What matters operationally is that this kit collapses a multi-step diagnostic pathway into a single point-of-care step. For procurement managers in hospital groups or preventive health networks, that reduces per-patient screening cost and removes dependency on centralized lab processing.

China’s industrial role here is in scaling antibody production and lateral flow manufacturing to make this price-accessible for mass screening programs — a capability built on decades of IVD supply chain experience.

Why it matters:
This kit does not diagnose dementia. It flags risk at a fraction of the cost and complexity of traditional methods, making large-scale early screening feasible for the first time in primary care settings across China and beyond.

View Product →